Plasma Protein Therapeutics Market

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Plasma Protein Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Plasma Protein Therapeutics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Phase 1 and Phase 2 Drugs (Qualitative Analyses)

    5.3. Phase 3 Drugs (Quantitative)

6. Global Plasma Protein Therapeutics Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        6.2.1. Immunoglobulin 

        6.2.2. Albumin 

        6.2.3. Coagulation Factor

        6.2.4. C1-esterase inhibitors

        6.2.5. Others

    6.3. Global Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        6.3.1. Hemophilia

        6.3.2. Primary Immunodeficiency Disorder (PID)

        6.3.3. Idiopathic Thrombocytopenic Purpura

        6.3.4. Secondary Immunodeficiency

        6.3.5. Hereditary Angioedema

        6.3.6. Other Indications

    6.4. Global Plasma Protein Therapeutics Market Attractiveness, by Product

    6.5. Global Plasma Protein Therapeutics Market Attractiveness, by Application

7. Global Plasma Protein Therapeutics Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Global Plasma Protein Therapeutics Market Value Forecast, by Region

        7.2.1. North America 

        7.2.2. Europe 

        7.2.3. Asia Pacific 

        7.2.4. Latin America 

        7.2.5. Middle East & Africa 

    7.3. Global Plasma Protein Therapeutics Market Attractiveness, by Region

8. North America Plasma Protein Therapeutics Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. North America Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        8.2.1. Immunoglobulin 

        8.2.2. Albumin 

        8.2.3. Coagulation Factor

        8.2.4. C1-esterase inhibitors

        8.2.5. Others

    8.3. North America Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        8.3.1. Hemophilia

        8.3.2. Primary Immunodeficiency Disorder (PID)

        8.3.3. Idiopathic Thrombocytopenic Purpura

        8.3.4. Secondary Immunodeficiency

        8.3.5. Hereditary Angioedema

        8.3.6. Other Indications

    8.4. North America Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027

        8.4.1. U.S.

        8.4.2. Canada

    8.5. North America Plasma Protein Therapeutics Market Attractiveness Analysis 

        8.5.1. By Product 

        8.5.2. By Application 

        8.5.3. By Country

9. Europe Plasma Protein Therapeutics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

10. Europe Plasma Protein Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        10.2.1. Immunoglobulin 

        10.2.2. Albumin 

        10.2.3. Coagulation Factor

        10.2.4. C1-esterase inhibitors

        10.2.5. Others

    10.3. Europe Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        10.3.1. Hemophilia

        10.3.2. Primary Immunodeficiency Disorder (PID)

        10.3.3. Idiopathic Thrombocytopenic Purpura

        10.3.4. Secondary Immunodeficiency

        10.3.5. Hereditary Angioedema

        10.3.6. Other Indications

    10.4. Europe Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe 

    10.5. Europe Plasma Protein Therapeutics Market Attractiveness Analysis 

        10.5.1. By Product

        10.5.2. By Application 

        10.5.3. By Country/Sub-region

11. Asia Pacific Plasma Protein Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        11.2.1. Immunoglobulin 

        11.2.2. Albumin 

        11.2.3. Coagulation Factor

        11.2.4. C1-esterase inhibitors

        11.2.5. Others

    11.3. Asia Pacific Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        11.3.1. Hemophilia

        11.3.2. Primary Immunodeficiency Disorder (PID)

        11.3.3. Idiopathic Thrombocytopenic Purpura

        11.3.4. Secondary Immunodeficiency

        11.3.5. Hereditary Angioedema

        11.3.6. Other Indications

    11.4. Asia Pacific Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific 

    11.5. Asia Pacific Plasma Protein Therapeutics Market Attractiveness Analysis 

        11.5.1. By Product

        11.5.2. By Application 

        11.5.3. By Country/Sub-region

12. Latin America Plasma Protein Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        12.2.1. Immunoglobulin 

        12.2.2. Albumin 

        12.2.3. Coagulation Factor

        12.2.4. C1-esterase inhibitors

        12.2.5. Others

    12.3. Latin America Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        12.3.1. Hemophilia

        12.3.2. Primary Immunodeficiency Disorder (PID)

        12.3.3. Idiopathic Thrombocytopenic Purpura

        12.3.4. Secondary Immunodeficiency

        12.3.5. Hereditary Angioedema

        12.3.6. Other Indications

    12.4. Latin America Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America Latin America 

    12.5. Latin America Plasma Protein Therapeutics Market Attractiveness Analysis 

        12.5.1. By Product

        12.5.2. By Application 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Plasma Protein Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Plasma Protein Therapeutics Market Value Forecast, by Product, 2017–2027

        13.2.1. Immunoglobulin 

        13.2.2. Albumin 

        13.2.3. Coagulation Factor

        13.2.4. C1-esterase inhibitors

        13.2.5. Others

    13.3. Middle East & Africa Plasma Protein Therapeutics Market Value Forecast, by Application, 2017–2027

        13.3.1. Hemophilia

        13.3.2. Primary Immunodeficiency Disorder (PID)

        13.3.3. Idiopathic Thrombocytopenic Purpura

        13.3.4. Secondary Immunodeficiency

        13.3.5. Hereditary Angioedema

        13.3.6. Other Indications

    13.4. Middle East & Africa Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa 

    13.5. Middle East & Africa Plasma Protein Therapeutics Market Attractiveness Analysis 

        13.5.1. By Product

        13.5.2. By Application 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Mergers & Acquisitions (M&A)

    14.2. Funding

    14.3. Company Profiles

        14.3.1. Dexcom, Inc. 

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Growth Strategies

            14.3.1.3. SWOT Analysis

        14.3.2. Apple, Inc. 

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Growth Strategies

            14.3.2.3. SWOT Analysis

        14.3.3. FitBit, Inc. 

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Growth Strategies

            14.3.3.3. SWOT Analysis

        14.3.4. Withings 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Growth Strategies

            14.3.4.3. SWOT Analysis

        14.3.5. Proteus Digital Health

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Growth Strategies

            14.3.5.3. SWOT Analysis

        14.3.6. Omada Health, Inc. 

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Growth Strategies

            14.3.6.3. SWOT Analysis 

        14.3.7. WellDoc, Inc. 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Growth Strategies

            14.3.7.3. SWOT Analysis

        14.3.8. Livongo Health 

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Growth Strategies

            14.3.8.3. SWOT Analysis

        14.3.9. Noom, Inc. 

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Growth Strategies

            14.3.9.3. SWOT Analysis

        14.3.10. Ginger.io, Inc. 

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Growth Strategies

            14.3.10.3. SWOT Analysis

        14.3.11. Propeller Health 

            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.11.2. Growth Strategies

            14.3.11.3. SWOT Analysis

        14.3.12. 2Morrow, Inc.

            14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.12.2. Growth Strategies

            14.3.12.3. SWOT Analysis

        14.3.13. Canary Health 

            14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.13.2. Growth Strategies

            14.3.13.3. SWOT Analysis

        14.3.14. Mango Health

            14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.14.2. Growth Strategies

            14.3.14.3. SWOT Analysis

        14.3.15. BiogeniQ Inc.

            14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.15.2. Growth Strategies

            14.3.15.3. SWOT Analysis

        14.3.16. Twine Health, Inc.

            14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.16.2. Growth Strategies

            14.3.16.3. SWOT Analysis

        14.3.17. Glooko, Inc.

            14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.17.2. Growth Strategies

            14.3.17.3. SWOT Analysis

        14.3.18. Firstbeat Technologies Ltd 

            14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.18.2. Growth Strategies

            14.3.18.3. SWOT Analysis

        14.3.19. Claritas MindSciences

            14.3.19.1.  Company Overview (HQ, Business Segments, Employee Strength)

            14.3.19.2. Growth Strategies

            14.3.19.3. SWOT Analysis

        14.3.20. Big Health 

            14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.20.2. Growth Strategies

            14.3.20.3. SWOT Analysis

        14.3.21. Dthera Sciences 

            14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.21.2. Growth Strategies

            14.3.21.3. SWOT Analysis

        14.3.22. Virta Health Corp

            14.3.22.1.  Company Overview (HQ, Business Segments, Employee Strength)

            14.3.22.2. Growth Strategies

            14.3.22.3. SWOT Analysis

        14.3.23. Zest Health, LLC 

            14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.23.2. Growth Strategies

            14.3.23.3. SWOT Analysis

        14.3.24. Meru Health, Inc.

            14.3.24.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.24.2. Growth Strategies

            14.3.24.3. SWOT Analysis

        14.3.25. HealthMine, Inc. 

            14.3.25.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.25.2. Growth Strategies

            14.3.25.3. SWOT Analysis

        14.3.26. Pear Therapeutics, Inc. 

            14.3.26.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.26.2. Growth Strategies

            14.3.26.3. SWOT Analysis

        14.3.27. BioTelemetry, Inc. 

            14.3.27.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.27.2. Growth Strategies

            14.3.27.3. SWOT Analysis

        14.3.28. Blue Mesa Health 

            14.3.28.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.28.2. Growth Strategies

            14.3.28.3. SWOT Analysis

        14.3.29. Digital Therapeutics 

            14.3.29.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.29.2. Growth Strategies

            14.3.29.3. SWOT Analysis

List of Tables

Table 1. Plasma Protein Therapeutics Market Snapshot

Table 2. Global Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 3. Global Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 4. Global Plasma Protein Therapeutics Market Revenue, by Region, (US$ Mn), 2017–2027

Table 5. Pipeline Analysis (Phase I and Phase II)

Table 6. Pipeline Analysis (Phase III): Plasma protein Therapeutics, Expected Launch date of Approval to 2027 (US$ Mn)

Table 7. North America Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 8. North America Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 9. Europe Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 10. Europe Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 11. Europe Plasma Protein Therapeutics Market Estimates and Forecast, by Countries, (US$ Mn), 2017–2027

Table 12. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 13. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 14. Asia Pacific Plasma Protein Therapeutics Market Estimates and Forecast, by Countries, (US$ Mn), 2017–2027

Table 15. LATAM Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2017–2027

Table 16. LATAM Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2017–2027

Table 17. Latin America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2017–2027

Table 18. ROW Plasma Protein Therapeutics Market Estimates and Forecast, by Product Type, (US$ Mn), 2017–2027

Table 19. ROW Plasma Protein Therapeutics Market Estimates and Forecast, by Application, (US$ Mn), 2017–2027

List of Figures

Figure 1. Global Plasma Protein Therapeutics Market Revenue, (US$ Mn), 2017–2027

Figure 2. Global Plasma Protein Therapeutics Market Revenue, by Product Type (US$ Mn), 2017–2027

Figure 3. Global Plasma Protein Therapeutics Market Revenue, by Application (US$ Mn), 2017–2027

Figure 4. Global Plasma Protein Therapeutics Market, by Geography (%), 2015

Figure 5. Global Plasma Protein Therapeutics Market, by Geography (%), 2024

Figure 6. Market Attractiveness Analysis, by Geography (2015)

Figure 7. Global Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 8. Global Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 9. Global Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 10. Global C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 11. Other Plasma-derived Proteins Market Revenue, (US$ Mn), 2017–2027

Figure 12. Global Hemophilia Market Revenue, (US$ Mn), 2017–2027

Figure 13. Global Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 14. Global Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 15. Global Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 16. Global Hereditary Angioedema Market Revenue, (US$ Mn), 2017–2027

Figure 17. Other Application Market Revenue, (US$ Mn), 2017–2027

Figure 18. Market Positioning of Key

Figure 19. North America Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 20. North America Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 21. North America Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 22. North America C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 23. North America Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 24. North America Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 25. North America Secondary Immunodeficiency Market Estimates and Forecast, (US$ Mn), 2017–2027

Figure 26. North America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2017–2027

Figure 27. Europe Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 28. Europe Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 29. Europe Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 30. Europe C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 31. Europe Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 32. Europe Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 33. Europe Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 34. Asia Pacific Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 35. Asia Pacific Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 36. Asia Pacific Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 37. Asia Pacific C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 38. Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 39. Asia Pacific Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 40. Asia Pacific Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 41. LATAM Immunoglobulin Market Revenue, (US$ Mn), 2017–2027

Figure 42. LATAM Albumin Market Revenue, (US$ Mn), 2017–2027

Figure 43. LATAM Coagulation Factor Market Revenue, (US$ Mn), 2017–2027

Figure 44. LATAM C1 Esterase inhibitors Market Revenue, (US$ Mn), 2017–2027

Figure 45. LATAM Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2017–2027

Figure 46. LATAM Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2017–2027

Figure 47. LATAM Secondary Immunodeficiency Market Revenue, (US$ Mn), 2017–2027

Figure 48. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 49. Geographical Financial Overview: 2017-2019(US$ Mn)

Figure 50. Financial Overview: 2017-2019(US$ Mn)

Figure 51. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 52. Geographical Overview: 2017-2019(US$ Mn)

Figure 53. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 54. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 55. Geographical Overview: 2017-2019(US$ Mn)

Figure 56. Financial Overview: 2012–2014 (US$ Mn)

Figure 57. Financial Overview: 2017-2019(US$ Mn)

Figure 58. Segmental Financial Overview: 2017-2019(US$ Mn)

Figure 59. Geographical Overview: 2017-2019(US$ Mn)